O	0	3	Use	Use	NN	B-NP
O	4	6	of	of	IN	B-PP
O	7	18	uteroglobin	uteroglobin	NN	B-NP
O	19	22	for	for	IN	B-PP
O	23	26	the	the	DT	B-NP
O	27	38	engineering	engineering	NN	I-NP
O	39	41	of	of	IN	B-PP
O	42	52	polyvalent	polyvalent	JJ	B-NP
O	52	53	,	,	,	I-NP
O	54	66	polyspecific	polyspecific	JJ	I-NP
O	67	73	fusion	fusion	NN	I-NP
O	74	82	proteins	protein	NNS	I-NP
O	82	83	.	.	.	O

O	84	86	We	We	PRP	B-NP
O	87	93	report	report	VBP	B-VP
O	94	95	a	a	DT	B-NP
O	96	101	novel	novel	JJ	I-NP
O	102	110	strategy	strategy	NN	I-NP
O	111	113	to	to	TO	B-PP
O	114	122	engineer	engineer	NN	B-NP
O	123	126	and	and	CC	O
O	127	134	express	express	VBP	B-VP
O	135	141	stable	stable	JJ	B-NP
O	142	145	and	and	CC	I-NP
O	146	153	soluble	soluble	JJ	I-NP
O	154	159	human	human	JJ	I-NP
O	160	171	recombinant	recombinant	JJ	I-NP
O	172	182	polyvalent	polyvalent	JJ	I-NP
O	182	183	/	/	SYM	I-NP
O	183	195	polyspecific	polyspecific	JJ	I-NP
O	196	202	fusion	fusion	NN	I-NP
O	203	211	proteins	protein	NNS	I-NP
O	211	212	.	.	.	O

O	213	216	The	The	DT	B-NP
O	217	226	procedure	procedure	NN	I-NP
O	227	229	is	be	VBZ	B-VP
O	230	235	based	base	VBN	I-VP
O	236	238	on	on	IN	B-PP
O	239	242	the	the	DT	B-NP
O	243	246	use	use	NN	I-NP
O	247	249	of	of	IN	B-PP
O	250	251	a	a	DT	B-NP
O	252	259	central	central	JJ	I-NP
O	260	268	skeleton	skeleton	NN	I-NP
O	269	271	of	of	IN	B-PP
O	272	283	uteroglobin	uteroglobin	NN	B-NP
O	283	284	,	,	,	O
O	285	286	a	a	DT	B-NP
O	287	292	small	small	JJ	I-NP
O	293	296	and	and	CC	O
O	297	301	very	very	RB	B-ADJP
O	302	309	soluble	soluble	JJ	I-ADJP
O	310	320	covalently	covalently	RB	B-VP
O	321	327	linked	link	VBN	I-VP
O	328	339	homodimeric	homodimeric	JJ	B-NP
O	340	347	protein	protein	NN	I-NP
O	348	352	that	that	WDT	B-NP
O	353	355	is	be	VBZ	B-VP
O	356	360	very	very	RB	B-ADJP
O	361	370	resistant	resistant	JJ	I-ADJP
O	371	373	to	to	TO	B-PP
O	374	385	proteolytic	proteolytic	JJ	B-NP
O	386	393	enzymes	enzyme	NNS	I-NP
O	394	397	and	and	CC	B-PP
O	398	400	to	to	TO	B-PP
O	401	403	pH	pH	NN	B-NP
O	404	414	variations	variation	NNS	I-NP
O	414	415	.	.	.	O

O	416	421	Using	Use	VBG	B-VP
O	422	423	a	a	DT	B-NP
O	424	429	human	human	JJ	I-NP
O	430	441	recombinant	recombinant	JJ	I-NP
O	442	450	antibody	antibody	NN	I-NP
O	451	452	(	(	(	O
O	452	456	scFv	scFv	NN	B-NP
O	456	457	)	)	)	O
O	458	466	specific	specific	JJ	B-ADJP
O	467	470	for	for	IN	B-PP
O	471	474	the	the	DT	B-NP
O	475	487	angiogenesis	angiogenesis	NN	I-NP
O	488	494	marker	marker	NN	I-NP
O	495	501	domain	domain	NN	I-NP
O	502	503	B	B	NN	I-NP
O	504	506	of	of	IN	B-PP
O	507	518	fibronectin	fibronectin	NN	B-NP
O	518	519	,	,	,	O
O	520	531	interleukin	interleukin	NN	B-NP
O	532	533	2	2	CD	I-NP
O	533	534	,	,	,	O
O	535	538	and	and	CC	O
O	539	541	an	an	DT	B-NP
O	542	546	scFv	scFv	NN	I-NP
O	547	551	able	able	JJ	B-ADJP
O	552	554	to	to	TO	B-VP
O	555	565	neutralize	neutralize	VB	I-VP
O	566	571	tumor	tumor	NN	B-NP
O	572	580	necrosis	necrosis	NN	I-NP
O	581	587	factor	factor	NN	I-NP
O	587	588	-	-	HYPH	O
O	588	593	alpha	alpha	SYM	B-NP
O	593	594	,	,	,	O
O	595	597	we	we	PRP	B-NP
O	598	607	expressed	express	VBD	B-VP
O	608	615	various	various	JJ	B-NP
O	616	628	biologically	biologically	RB	I-NP
O	629	635	active	active	JJ	I-NP
O	636	647	uteroglobin	uteroglobin	NN	I-NP
O	648	654	fusion	fusion	NN	I-NP
O	655	663	proteins	protein	NNS	I-NP
O	663	664	.	.	.	O

O	665	668	The	The	DT	B-NP
O	669	676	results	result	NNS	I-NP
O	677	688	demonstrate	demonstrate	VBP	B-VP
O	689	692	the	the	DT	B-NP
O	693	704	possibility	possibility	NN	I-NP
O	705	707	to	to	TO	B-VP
O	708	716	generate	generate	VB	I-VP
O	717	729	monospecific	monospecific	JJ	B-NP
O	730	738	divalent	divalent	JJ	I-NP
O	739	742	and	and	CC	I-NP
O	743	754	tetravalent	tetravalent	JJ	I-NP
O	755	765	antibodies	antibody	NNS	I-NP
O	765	766	,	,	,	O
O	767	782	immunocytokines	immunocytokine	NNS	B-NP
O	782	783	,	,	,	O
O	784	787	and	and	CC	O
O	788	792	dual	dual	JJ	B-NP
O	793	804	specificity	specificity	NN	I-NP
O	805	816	tetravalent	tetravalent	JJ	I-NP
O	817	827	antibodies	antibody	NNS	I-NP
O	827	828	.	.	.	O

O	829	840	Furthermore	Furthermore	RB	B-ADVP
O	840	841	,	,	,	O
O	842	850	compared	compare	VBN	B-PP
O	851	855	with	with	IN	B-PP
O	856	863	similar	similar	JJ	B-NP
O	864	870	fusion	fusion	NN	I-NP
O	871	879	proteins	protein	NNS	I-NP
O	880	882	in	in	IN	B-PP
O	883	888	which	which	WDT	B-NP
O	889	900	uteroglobin	uteroglobin	NN	B-NP
O	901	904	was	be	VBD	B-VP
O	905	908	not	not	RB	I-VP
O	909	913	used	use	VBN	I-VP
O	913	914	,	,	,	O
O	915	918	the	the	DT	B-NP
O	919	922	use	use	NN	I-NP
O	923	925	of	of	IN	B-PP
O	926	937	uteroglobin	uteroglobin	NN	B-NP
O	938	946	improved	improve	VBD	B-VP
O	947	957	properties	property	NNS	B-NP
O	958	960	of	of	IN	B-PP
O	961	971	solubility	solubility	NN	B-NP
O	972	975	and	and	CC	I-NP
O	976	985	stability	stability	NN	I-NP
O	985	986	.	.	.	O

O	987	993	Indeed	Indeed	RB	B-ADVP
O	993	994	,	,	,	O
O	995	997	in	in	IN	B-PP
O	998	1001	the	the	DT	B-NP
O	1002	1010	reported	report	VBN	I-NP
O	1011	1016	cases	case	NNS	I-NP
O	1017	1019	it	it	PRP	B-NP
O	1020	1023	was	be	VBD	B-VP
O	1024	1032	possible	possible	JJ	B-ADJP
O	1033	1035	to	to	TO	B-VP
O	1036	1042	vacuum	vacuum	VB	I-VP
O	1043	1046	dry	dry	JJ	B-NP
O	1047	1050	and	and	CC	O
O	1051	1063	reconstitute	reconstitute	VB	B-VP
O	1064	1067	the	the	DT	B-NP
O	1068	1076	proteins	protein	NNS	I-NP
O	1077	1084	without	without	IN	B-PP
O	1085	1088	any	any	DT	B-NP
O	1089	1100	aggregation	aggregation	NN	I-NP
O	1101	1103	or	or	CC	I-NP
O	1104	1108	loss	loss	NN	I-NP
O	1109	1111	in	in	IN	B-PP
O	1112	1119	protein	protein	NN	B-NP
O	1120	1123	and	and	CC	O
O	1124	1134	biological	biological	JJ	B-NP
O	1135	1143	activity	activity	NN	I-NP
O	1143	1144	.	.	.	O

